Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function
First Claim
1. A method of treating a xenogeneic subject suffering from a disorder characterized by decreased liver function, comprisingi) isolating a population of porcine hepatocytes ii) altering the hepatocytes by contacting the hepatocytes prior to introduction into a subject with at least one anti-MAC class I antibody, which binds to the MHC class I antigen on the cell surface but does not activate complement or induce lysis of the cells such that rejection of the hepatocytes is inhibited upon introduction of the cells into the xenogeneic subject;
- and iii) administering the porcine hepatocytes to the liver of the subject while decreasing portal blood pressure of the subject to thereby treat a xenogeneic subject suffering from a disorder characterized by decreased liver function.
4 Assignments
0 Petitions
Accused Products
Abstract
Isolated porcine hepatocytes, isolated populations of such hepatocytes and methods for using the hepatocytes to treat subjects with disorders characterized by insufficient liver function are described. The porcine hepatocytes can be either hepatocytes isolated from adult, immature, or embryonic swine. The porcine hepatocytes can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof). The isolated porcine hepatocytes of the invention can be used to treat disorders characterized by insufficient liver function by administering the hepatocytes to a subject having such a disorder.
31 Citations
29 Claims
-
1. A method of treating a xenogeneic subject suffering from a disorder characterized by decreased liver function, comprising
i) isolating a population of porcine hepatocytes ii) altering the hepatocytes by contacting the hepatocytes prior to introduction into a subject with at least one anti-MAC class I antibody, which binds to the MHC class I antigen on the cell surface but does not activate complement or induce lysis of the cells such that rejection of the hepatocytes is inhibited upon introduction of the cells into the xenogeneic subject; - and
iii) administering the porcine hepatocytes to the liver of the subject while decreasing portal blood pressure of the subject to thereby treat a xenogeneic subject suffering from a disorder characterized by decreased liver function. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- and
-
15. A method of treating a xenogeneic subject suffering from a disorder characterized by decreased liver function, comprising
i) isolating a population of porcine hepatocytes ii) altering said porcine hepatocytes by contacting the hepatocytes prior to introduction into a subject with monoclonal antibody PT85, which binds to the MHC class I antigen on the cell surface but does not activate complement or induce lysis of the hepatocytes such that rejection of the cells is inhibited upon introduction of the hepatocytes into the xenogeneic subject; - and
iii) administering the porcine hepatocytes to the liver of the subject while decreasing portal blood pressure of the subject to thereby treat a xenogeneic subject suffering from a disorder characterized by decreased liver function.
- and
-
16. A method of treating a xenogeneic subject suffering from a disorder characterized by decreased liver function, comprising
i) isolating a population of porcine hepatocytes ii) altering the porcine hepatocytes by contacting the hepatocytes prior to introduction into a subject with at least one F(ab′ - )2 fragment of an anti-MHC class I antibody, which binds to the MHC class I antigen on the cell surface but does not activate complement or induce lysis of the hepatocytes such that rejection of the hepatocytes is inhibited upon introduction of the hepatocytes into the xenogeneic subject;
iii) administering the porcine hepatocytes to the liver of the subject while decreasing portal blood pressure of the subject to thereby treat a xenogeneic subject suffering from a disorder characterized by decreased liver function. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
- )2 fragment of an anti-MHC class I antibody, which binds to the MHC class I antigen on the cell surface but does not activate complement or induce lysis of the hepatocytes such that rejection of the hepatocytes is inhibited upon introduction of the hepatocytes into the xenogeneic subject;
Specification